| 臺大學術典藏 |
2018-09-10T08:31:55Z |
Aboriginal Taiwanese hepatitis B carriers have more favorable viral factors than Han Chinese carriers
|
Nien, Hsiao-Ching;Sheu, Jin-Chuan;Kao, Jia-Horng;Chou, Huei-Chi;Su, Chien-Wen;Chen, Chien-Hung; JIN-CHUAN SHEU; JIA-HORNG KAO; NIEN, HSIAO-CHING; SHEU, JIN-CHUAN; KAO, JIA-HORNG; CHOU, HUEI-CHI; SU, CHIEN-WEN; CHEN, CHIEN-HUNG |
| 臺大學術典藏 |
2018-09-10T08:31:41Z |
Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy
|
Tseng, T.-C. ;Yu, M.-L.; Liu, C.-J.; Lin, C.-L. ;Huang, Y.-W.; Hsu, C.-S.; Liu, C.-H.; Kuo, S.F.-T. ;Pan, C.J.-H. ;Yang, S.-S. ;Su, C.-W. ;Chen, P.-J.; Chen, D.-S.; Kao, J.-H.; YI-WEN HUANG; CHUN-JEN LIU; PEI-JER CHEN; CHEN-HUA LIU; DING-SHINN CHEN; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:30:13Z |
Treatment of hepatitis C virus infection in patients with end-stage renal disease
|
Liu, C.-H.;Kao, J.-H.; CHEN-HUA LIU; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:30:08Z |
Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.
|
Chun-Jen Liu;Pei-Jer Chen;Chen-Hua Liu;Ding-Shinn Chen;Jia-Horng Kao; CHUN-JEN LIU; PEI-JER CHEN; CHEN-HUA LIU; DING-SHINN CHEN; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:30:08Z |
Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.
|
Chun-Jen Liu;Pei-Jer Chen;Chen-Hua Liu;Ding-Shinn Chen;Jia-Horng Kao; CHUN-JEN LIU; PEI-JER CHEN; CHEN-HUA LIU; DING-SHINN CHEN; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:30:08Z |
HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection.
|
Chun-Jen Liu;Pei-Jer Chen;Chen-Hua Liu;Ding-Shinn Chen;Jia-Horng Kao; CHUN-JEN LIU; PEI-JER CHEN; CHEN-HUA LIU; DING-SHINN CHEN; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:30:08Z |
HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection.
|
Chun-Jen Liu;Pei-Jer Chen;Chen-Hua Liu;Ding-Shinn Chen;Jia-Horng Kao; CHUN-JEN LIU; PEI-JER CHEN; CHEN-HUA LIU; DING-SHINN CHEN; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:30:07Z |
Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives.
|
Chen-Hua Liu;Jia-Horng Kao; CHEN-HUA LIU; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:30:07Z |
Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives.
|
Chen-Hua Liu;Jia-Horng Kao; CHEN-HUA LIU; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:30:07Z |
Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan.
|
Chun-Jen Liu;Pei-Jer Chen;Chen-Hua Liu;Ding-Shinn Chen;Jia-Horng Kao; CHUN-JEN LIU; PEI-JER CHEN; CHEN-HUA LIU; DING-SHINN CHEN; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:30:07Z |
Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan.
|
Chun-Jen Liu;Pei-Jer Chen;Chen-Hua Liu;Ding-Shinn Chen;Jia-Horng Kao; CHUN-JEN LIU; PEI-JER CHEN; CHEN-HUA LIU; DING-SHINN CHEN; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:28:55Z |
Risk factors of hepatitis during Anti-tuberculous treatment and implications of hepatitis virus load
|
Wang, J.-Y.;Liu, C.-H.;Hu, F.-C.;Chang, H.-C.;Liu, J.-L.;Chen, J.-M.;Yu, C.-J.;Lee, L.-N.;Kao, J.-H.;Yang, P.-C.; LI-NA LEE; Chong-Jen Yu; JANN-YUAN WANG; CHEN-HUA LIU; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:16:50Z |
Rifaximin treatment in hepatic encephalopathy [1]
|
Wang, C.-C.;Kao, J.-H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:16:50Z |
Role of Viral Factors in Modifying Weight-Related Effects on Disease Progression of Chronic Hepatitis C Patients
|
Hsu, C.;Kao, J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:16:50Z |
Treatment of chronic hepatitis B in Asia-Pacific countries: Is the Asia-Pacific consensus statement being followed?
|
Sung, J.J.Y.;Amarapurkar, D.;Chan, H.L.Y.;Cheng, J.;Kao, J.-H.;Han, K.-H.;Piratvisuth, T.; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:16:50Z |
Use of statins and gallstone risk [1]
|
Hsu, C.-S.;Kao, J.-H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:16:50Z |
慢性丙型肝炎治疗的新进展：从病毒到宿主
|
許景盛;高嘉宏; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:16:49Z |
Intrathecal delivery of a mutant μ-opioid receptor activated by naloxone as a possible antinociceptive paradigm
|
Kao, J.H.;Chen, S.L.;Ma, H.I.;Law, P.Y.;Tao, P.L.;Loh, H.H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:16:49Z |
Letter to the editor
|
Wang, C.-C.;Kao, J.-H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:16:49Z |
Metformin improves sustained virologic response in difficult-to-cure hepatitis c: More questions than answers
|
Wang, C.-C.;Kao, J.-H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:16:49Z |
Optimal management of hepatocellular carcinoma: Challenges and opportunities
|
Lin, C.-L.;Kao, J.-H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:16:49Z |
Outcomes of HCV treatment: Who does well and who does not?
|
Hsu, C.-S.;Kao, J.-H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:16:49Z |
Preoperative drainage in pancreatic cancer
|
Wang, C.-C.;Kao, J.-H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:16:48Z |
Clinical implications of hepatitis B virus variants
|
Lin, C.-L.;Kao, J.-H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:16:48Z |
Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy
|
Lui, Y.Y.-N.;Tsoi, K.K.-F.;Wong, V.W.-S.;Kao, J.-H.;Hou, J.-L.;Teo, E.-K.;Mohamed, R.;Piratvisuth, T.;Han, K.-H.;Mihm, U.;Wong, G.L.-H.;Chan, H.L.-Y.; JIA-HORNG KAO |
